265 related articles for article (PubMed ID: 32041519)
1. The role of RICTOR amplification in targeted therapy and drug resistance.
Zhao D; Jiang M; Zhang X; Hou H
Mol Med; 2020 Feb; 26(1):20. PubMed ID: 32041519
[TBL] [Abstract][Full Text] [Related]
2. The role of RICTOR downstream of receptor tyrosine kinase in cancers.
Jebali A; Dumaz N
Mol Cancer; 2018 Feb; 17(1):39. PubMed ID: 29455662
[TBL] [Abstract][Full Text] [Related]
3. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.
Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V
Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840
[TBL] [Abstract][Full Text] [Related]
4. Rictor promotes tumor progression of rapamycin-insensitive triple-negative breast cancer cells.
Watanabe R; Miyata M; Oneyama C
Biochem Biophys Res Commun; 2020 Oct; 531(4):636-642. PubMed ID: 32819718
[TBL] [Abstract][Full Text] [Related]
5. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
6. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications.
Fourneaux B; Chaire V; Lucchesi C; Karanian M; Pineau R; Laroche-Clary A; Italiano A
Oncotarget; 2017 Jan; 8(5):7878-7890. PubMed ID: 28002802
[TBL] [Abstract][Full Text] [Related]
8. RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.
Sakre N; Wildey G; Behtaj M; Kresak A; Yang M; Fu P; Dowlati A
Oncotarget; 2017 Jan; 8(4):5992-6002. PubMed ID: 27863413
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
10. Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
Werfel TA; Wang S; Jackson MA; Kavanaugh TE; Joly MM; Lee LH; Hicks DJ; Sanchez V; Ericsson PG; Kilchrist KV; Dimobi SC; Sarett SM; Brantley-Sieders DM; Cook RS; Duvall CL
Cancer Res; 2018 Apr; 78(7):1845-1858. PubMed ID: 29358172
[TBL] [Abstract][Full Text] [Related]
11. Rictor regulates the vasculogenic mimicry of melanoma via the AKT-MMP-2/9 pathway.
Liang X; Sun R; Zhao X; Zhang Y; Gu Q; Dong X; Zhang D; Sun J; Sun B
J Cell Mol Med; 2017 Dec; 21(12):3579-3591. PubMed ID: 28699701
[TBL] [Abstract][Full Text] [Related]
12. Correlation between RICTOR overexpression and amplification in advanced solid tumors.
Bang H; Ahn S; Ji Kim E; Kim ST; Park HY; Lee J; Kim KM
Pathol Res Pract; 2020 Jan; 216(1):152734. PubMed ID: 31740232
[TBL] [Abstract][Full Text] [Related]
13. RICTOR gene amplification is correlated with metastasis and therapeutic resistance in triple-negative breast cancer.
El Shamieh S; Saleh F; Moussa S; Kattan J; Farhat F
Pharmacogenomics; 2018 Jun; 19(9):757-760. PubMed ID: 29790419
[TBL] [Abstract][Full Text] [Related]
14. RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.
Cheng H; Zou Y; Ross JS; Wang K; Liu X; Halmos B; Ali SM; Liu H; Verma A; Montagna C; Chachoua A; Goel S; Schwartz EL; Zhu C; Shan J; Yu Y; Gritsman K; Yelensky R; Lipson D; Otto G; Hawryluk M; Stephens PJ; Miller VA; Piperdi B; Perez-Soler R
Cancer Discov; 2015 Dec; 5(12):1262-70. PubMed ID: 26370156
[TBL] [Abstract][Full Text] [Related]
15. Receptor Tyrosine Kinase-Targeted Cancer Therapy.
Yamaoka T; Kusumoto S; Ando K; Ohba M; Ohmori T
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30404198
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of mTORC2 component RICTOR impairs tumor growth in pancreatic cancer models.
Schmidt KM; Hellerbrand C; Ruemmele P; Michalski CW; Kong B; Kroemer A; Hackl C; Schlitt HJ; Geissler EK; Lang SA
Oncotarget; 2017 Apr; 8(15):24491-24505. PubMed ID: 28445935
[TBL] [Abstract][Full Text] [Related]
17. Rituximab effectively reverses Tyrosine kinase inhibitors (TKIs) resistance through inhibiting the accumulation of rictor on mitochondria-associated ER-membrane (MAM).
Xu ZH; Liu CH; Hang JB; Gao BL; Hu JA
Cancer Biomark; 2017 Dec; 20(4):581-588. PubMed ID: 28946557
[TBL] [Abstract][Full Text] [Related]
18. A Comprehensive Pan-Cancer Analysis of the Potential Biological Functions and Prognosis Values of RICTOR.
Sun Y; Li R; Nong B; Songyang Z; Wang X; Ma W; Zhou Q
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372460
[TBL] [Abstract][Full Text] [Related]
19. Differential roles and activation of mammalian target of rapamycin complexes 1 and 2 during cell migration in prostate cancer cells.
Venugopal SV; Caggia S; Gambrell-Sanders D; Khan SA
Prostate; 2020 Apr; 80(5):412-423. PubMed ID: 31995655
[TBL] [Abstract][Full Text] [Related]
20. Identification of rictor as a novel substrate of Polo-like kinase 1.
Shao T; Liu X
Cell Cycle; 2015; 14(5):755-60. PubMed ID: 25714006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
